Muscle cell-mediated gene delivery to the rotator cuff.

Area of Science:

• Orthopedics
• Regenerative Medicine
• Cell Biology

Background:

• Rotator cuff lesions cause significant upper extremity disability.
• Current surgical treatments do not address intrinsic factors like aging and inflammation.
• Novel therapeutic strategies are needed for intrinsic rotator cuff pathologies.

Purpose of the Study:

• To characterize genetically engineered muscle-derived cells (MDCs).
• To evaluate the in vivo behavior and differentiation of MDCs after injection into rotator cuff tendons.
• To explore the potential of MDCs in tissue engineering for tendon repair.

Main Methods:

• Genetically engineered, highly purified MDCs were characterized in vitro.
• MDCs were injected into the supraspinatus tendons of nude rats.
• Injected cells were monitored for 3 weeks using marker gene expression and histological analysis.

Main Results:

• In vitro, MDCs showed no vimentin expression and high purity (98% beta-galactosidase positive, 99% mouse probe positive).
• In vivo, beta-galactosidase expression was detected up to 21 days post-injection.
• From day 7, injected cells adopted spindle shapes, integrated into collagen bundles, and differentiated into vimentin-expressing fibroblasts.

Conclusions:

• Rotator cuff tendon environment modulated injected MDCs toward a fibroblastic phenotype.
• MDCs demonstrated compatibility and differentiation potential, suggesting utility in tendon tissue engineering.
• This approach supports the use of muscle-derived progenitor cells and ex vivo gene therapy for rotator cuff lesions.